Serving Oregon and the Northwest since 1989, our vision is to add life to years, not simply years to life.
Member:
Guariglia, Robin, RN
Human blood plasma samples from participants in a variety of brain-related studies, including OADC clinic recruited subjects, Oregon Brain Aging Study, Community Brain Donor Program, Preventing Cognitive Decline with Alternative Therapies, African American Dementia and aging Project, Klamath Exceptional Aging Project, Late Onset Familial Alzheimer Disease Kindreds.
Tissue samples from brains of individuals who have been followed longitudinally in the Oregon Alzheimer’s Disease Center Clinical Core.
Human CSF samples from participants in a variety of brain-related studies, including OADC clinic recruited subjects, Oregon Brain Aging Study, Community Brain Donor Program, Preventing Cognitive Decline with Alternative Therapies, African American Dementia and aging Project, Klamath Exceptional Aging Project, Late Onset Familial Alzheimer Disease Kindreds.
Human genomic DNA samples from participants in a variety of brain-related studies, including OADC clinic recruited subjects, Oregon Brain Aging Study, Community Brain Donor Program, Preventing Cognitive Decline with Alternative Therapies, African American Dementia and aging Project, Klamath Exceptional Aging Project, Late Onset Familial Alzheimer Disease Kindreds.
Includes: Data and measures derived from in-home assessment technologies (e.g., walking speed, total activity, patterns of activity over time), data and measures derived from computer use (e.g., total computer use, average time in application, inter-keystroke interval; note that which websites are visited or what whole words are typed are NOT collected due to privacy considerations), data from weekly on-line health questionnaires (e.g., falls, depression, medication changes); note that this information is collected monthly by telephone for subjects who do not use a computer.
Data and measures derived from bed mats or load cells on the bed (e.g., total time in bed, sleep restlessness), data and measures derived from use of MedTracker device (e.g., percent compliance, time of pill taking), data and measures derived from additional in-home technologies (e.g., GPS cell phones)
"Genotypes Data:
APOE
Genome-Wide and candidate region SNP marker data on various platforms*
AD Candidate gene markers* (e.g. CYP46, MTHFR, HLA, Tau)
* These are available only on a limited subset of subjects."